[1] |
BERGER J,FORSS-PETTER S,EICHLER F S.Pathophysiology of X-linked adrenoleukodystrophy[J]. Biochim,2014,98(100):135-142.
|
[2] |
KEMPER A R,BROSCO J,COMEAU A M,et al.Newborn screening for X-linked adrenoleukodystrophy:evidence summary and advisory committee recommendation[J]. Genet Med,2017,19(1):121-126.
|
[3] |
TURGEON C T,MOSER A B,MØRKRID L,et al. Streamlined determination of lysophosphatidylcholines in dried blood spots for newborn screening of X-linked adrenoleukodystrophy[J]. Mol Genet Metab,2015,114(1):46-50.
|
[4] |
BOEHM C D,CUTTING G R,LACHTERMACHER M B,et al.Accurate DNA-based diagnostic and carrier testing for X-linked adrenoleukodystrophy[J]. Mol Genet Metab,1999,66(2):128-136.
|
[5] |
WU C,IWAMOTO T,IGARASHI J,et al.Application of a diagnostic methodology by quantification of 26:0 lysophosphatidylcholine in dried blood spots for Japanese newborn screening of X-linked adrenoleukodystrophy[J]. Mol Genet Metab Rep,2017,12:115-118.
|
[6] |
VAN DE BEEK M C,DIJKSTRA I M,VAN LENTHE H,et al. C26:0-carnitine is a new biomarker for X-linked adrenoleukodystrophy in mice and man[J]. PLoS One,2016,11(4): e0154597.
|
[7] |
BEZMAN L,MOSER A B,RAYMOND G V,et al.Adrenoleukodystrophy:incidence,new mutation rate,and results of extended family screening[J]. Ann Neurol,2001,49(4):512-517.
|
[8] |
MOSER H W,MAHMOOD A,RAYMOND G V.X-linked adrenoleukodystrophy[J]. Nat Clin Pract Neurol,2007,3(3):140-151.
|
[9] |
MAHMOOD A,RAYMOND G V,DUBEY P,et al.Survival analysis of haematopoietic cell transplantation for childhood cerebral X-linked adrenoleukodystrophy:a comparison study[J]. Lancet Neurol,2007,6(8):687-692.
|
[10] |
RAJABI F.Updates in newborn screening[J]. Pediatr Ann,2018,47(5):e187-e190.
|
[11] |
VOGEL B H,BRADLEY S E,ADAMS D J,et al.Newborn screening for X-linked adrenoleukodystrophy in New York State:diagnostic protocol,surveillance protocol and treatment guidelines[J]. Mol Genet Metab,2015,114(4):599-603.
|
[12] |
KEMPER A R,BROSCO J,COMEAU A M,et al.Newborn screening for X-linked adrenoleukodystrophy: evidence summary and advisory committee recommendation[J]. Genet Med,2017,19(1):121-126.
|
[13] |
BASSEY A,CHILCOTT J B,LEAVISS J,et al.Economic impact of screening for X-linked adrenoleukodystrophy within a newborn blood spot screening program[J]. Orphanet J Rare Dis,2018,13:179-190.
|
[14] |
韩鎏,倪君君,相婷,等. 液相色谱-串联质谱方法检测血清中极长链脂肪酸含量[J]. 中华检验医学杂志,2011,34(1):30-35.
|
[15] |
魏虹,应艳琴,梁雁,等. 血浆极长链脂肪酸GC-MS测定方法的建立和应用[J]. 临床儿科杂志,2005,23(8):519-522.
|
[16] |
MOSER A B,KREITER N,BEZMAN L,et al.Plasma very long chain fatty acids in 3 000 peroxisome disease patients and 29 000 controls[J]. Ann Neurol,1999,45(1):100-110.
|
[17] |
HUBBARD W C,MOSER A B,TORTORELLI S,et al.Combined liquid chromatography-tandem mass spectrometry as an analytical method for high throughput screening for X-linked adrenoleukodystrophy and other peroxisomal disorders:preliminary findings[J]. Mol Genet Metab,2006,89(1-2):185-187.
|
[18] |
HUFFNAGEL I C,VAN DE BEEK M C,SHOWERS A L,et al. Comparison of C26:0-carnitine and C26:0-lysophosphatidylcholine as diagnostic markers in dried blood spots from newborns and patients with adrenoleukodystrophy[J]. Mol Genet Metab,2017,122(4):209-215.
|
[19] |
TURGEON C T,MOSER A B,MØRKRID L,et al. Streamlined determination of lysophosphatidylcholines in dried blood spots for newborn screening of X-linked adrenoleukodystrophy[J]. Mol Genet Metab,2015,114(1):46-50.
|